anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Post-exertional malaise (PEM), the hallmark symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), represents a constellation of abnormal responses to physical, cognitive, and/or emotional exertion including profound fatigue, cognitive dysfunction, and exertion intolerance, among numerous other maladies. Two sequential cardiopulmonary exercise tests (2-d CPET) provide objective evidence of abnormal responses to exertion in ME/CFS but validated only in studies with small sample sizes. Further, translation of results to impairment status and approaches to symptom reduction are lacking.
METHODS: Participants with ME/CFS (Canadian Criteria; n = 84) and sedentary controls (CTL; n = 71) completed two CPETs on a cycle ergometer separated by 24 h. Two-way repeated measures ANOVA compared CPET measures at rest, ventilatory/anaerobic threshold (VAT), and peak effort between phenotypes and CPETs. Intraclass correlations described stability of CPET measures across tests, and relevant objective CPET data indicated impairment status. A subset of case-control pairs (n = 55) matched for aerobic capacity, age, and sex, were also analyzed.
RESULTS: Unlike CTL, ME/CFS failed to reproduce CPET-1 measures during CPET-2 with significant declines at peak exertion in work, exercise time, V ˙  e, V ˙  O2, V ˙  CO2, V ˙  T, HR, O2pulse, DBP, and RPP. Likewise, CPET-2 declines were observed at VAT for V ˙  e/ V ˙  CO2, PetCO2, O2pulse, work, V ˙  O2 and SBP. Perception of effort (RPE) exceeded maximum effort criteria for ME/CFS and CTL on both CPETs. Results were similar in matched pairs. Intraclass correlations revealed greater stability in CPET variables across test days in CTL compared to ME/CFS owing to CPET-2 declines in ME/CFS. Lastly, CPET-2 data signaled more severe impairment status for ME/CFS compared to CPET-1.
CONCLUSIONS: Presently, this is the largest 2-d CPET study of ME/CFS to substantiate impaired recovery in ME/CFS following an exertional stressor. Abnormal post-exertional CPET responses persisted compared to CTL matched for aerobic capacity, indicating that fitness level does not predispose to exertion intolerance in ME/CFS. Moreover, contributions to exertion intolerance in ME/CFS by disrupted cardiac, pulmonary, and metabolic factors implicates autonomic nervous system dysregulation of blood flow and oxygen delivery for energy metabolism. The observable declines in post-exertional energy metabolism translate notably to a worsening of impairment status. Treatment considerations to address tangible reductions in physiological function are proffered.
TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, retrospectively registered, ID# NCT04026425, date of registration: 2019-07-17.
The present invention relates to a Shentong capsule and a processing method thereof. The capsule is prepared from 70 to 90g of astragalus root, 30 to 50g of ginseng, 30 to 50g of ganoderma, 15 to 40g of cordyceps, 70 to 90g of earthworm, 30 to 50g of chuanxiong rhizome, 30 to 50g of Chinese angelica, 70 to 90g of caulis spatholobi, 30 to 50g of safflower, 30 to 50g of achyranthes root, 30 to 50g of peach kernel, 30 to 50g of red peony root, 30 to 50g of cassia twig, 30 to 50g of myrrh and 70 to 90g of red sage root. The ginseng, the cordyceps, the earthworm, the chuanxiong rhizome, the Chinese angelica and the cassia twig are mixed into fine powder according to a formulation. In the formulation, other eight kinds of medicine are crushed and are decocted by two time by adding water. A filtered liquid is combined and is concentrated into extractum. The extractum is mixed with the fine powder, is dried, is crushed, is screened and is respectively capsulized into a Shentong capsule. A clinical total effective rate reaches 89.15%.
FIELD: agriculture. ^ SUBSTANCE: insecticide agent is a dispersion which, in addition to water, contains 0.5-20 wt % hydrophobic silica, 0.01-10 wt % gelating or viscosity increasing additive, 0.1-1 wt % preservative and 0-1 wt % surface active substance with density ranging from 0.6 g/ml to approximately 1.02 g/ml. The method by which the insecticide agent is produced involves dispersing separate components successively or together in water and deaeration of separate components before and/or when adding or deaerating the dispersion during separate dispersion stages. The invention provides for obtaining an effective agent for fighting house dust mites - Dermatophagoides pteronyssimis, red mite - Dermanyssus gallinae, red flour beetle - Tribolium castaneum, wheat weevil - Sitophilus granaries, Indean meal moth - Plodia interpimctella, green bug - Schiazaphis graminum. ^ EFFECT: increased effectiveness of pesticide agent. ^ 4 cl, 1 tbl, 3 ex
PURPOSE:To obtain gel composed of a hydrated polymer, which has an excellent function of restoring deformation caused by an external force, is elastic and can adhere tightly to a container having a desired shape, by photopolymerizing a specified vinyl compd. in the presence of a photopolymerization initiator and a hydrophilic medium in a light-transmissible container made of a synthetic resin. CONSTITUTION:A vinyl compd. (A) obtd. by mixing at least 80wt% at least one water-soluble vinyl compd. selected from the group consisting of (meth)arylic acid, crotonic acid, itaconic acid and water-soluble salts thereof with not more than 20wt% at least one copolymerizable vinyl compd. selected fro the group consisting of alkoxyalkyl (meth)acrylates, vinyl acetate, styrene, etc. is blended with water or a hydrophilic medium (B) composed of water contg. methanol, isopropanol, ethylene glycol, etc. and a photopolymerization initiator (C) which does not release D2 or N2 by light (e.g., 1-hydroxycyclohexyl phenyl ketone), etc. to obtain an aq. polymerizable soln. The soln. is placed in a light- transmissible container having a light transmittance of not lower than 10% and made of a synthetic resin and photopolymerized.
PURPOSE:To improve fitting feeling, moldability when it is molded and peelability between a denture base and a denture base stabilized sheet after the denture base is used by stabilizing a denture consisting of a compsn. contg. an ethyl methacrylate polymer, butylphthalylbutyl glycolate and glyceryl triacetate at a specified ratio. CONSTITUTION:41-43wt.%, pref. 41.5-42.5wt.% ethyl methacrylate polymer, 37-39wt.%, pref. 37-38wt.% butylphthalylbutyl glycolate and 17-23wt.%, pref. 19-21.5wt.% glyceryl triacetate and 0.01-0.3wt.% titanium oxide are mixed. The resultant mixture is thoroughly kneaded and the kneaded compsn. is treated by means of a heat-prees to make it into a sheet, which is then punched into a required trapezoid to obtain a molding for a denture base stabilized sheet.
The spondyloarthropathies are a group of conditions characterised by spinal joint pain and have related clinical, epidemiological and genetic-related features. Ankylosing spondylitis, reactive arthritis, the spinal form of psoriatic arthritis and Crohn's and colitis enteropathic arthritis are the major clinical entities of the spondyloarthropathies, and principally occur in HLA-B27 positive individuals. Ankylosing spondylitis is much more common in males than females. Patients are usually seronegative for rheumatoid factor, and extra-articular features including iridocyclitis, mucous membrane and skin lesions: aortitis, may occur in some patients. The reactive arthritis form classically occurs following an infection of the gastrointestinal or genitourinary tract. The Crohn's and colitis enteropathic arthritis forms often have an associated large joint asymmetrical arthritis. Also discussed are acute rheumatic fever and Lyme disease which are conditions where the individual develops arthritis after an infection.
Participants diagnosed with RR cHL at the time of enrollment and RR cHL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed cHL, or RR cHL at the time of enrolment, or RR cHL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
A process for controlling the produc on of urease by bioﬁlm forming bacteria by treatment with N- acetyl cysteine (NAC). A process of preven ng catheter bacterial encrusta on by treatment with NAC. A process of inhibi ng the urease secreted by P. mirabilis isolates by treatment with NAC. A process of inhibi ng bacterial migra on through catheter segments by treatment with NAC. A process of reducing the elemental proﬁle of a catheter bioﬁlm by treatment with NAC. A process of reducing the inﬂammatory response of cells to urease by treatment with NAC. A process of reducing the level of bladder epithelial cell invasion by treatment with NAC. The NAC may be used alone or in combina on with one or more an bio cs and/or as a formula on.
In a double-blind study, 1092 patients with mild-to-moderate hypertension were randomized to once daily TOPROL-XL (25, 100, or 400 mg), PLENDIL® (felodipine extended-release tablets), the combination, or placebo. After 9 weeks, TOPROL-XL alone decreased sitting blood pressure by 6-8/4-7 mmHg (placebo-corrected change from baseline) at 24 hours post-dose. The combination of TOPROL-XL with PLENDIL has greater effects on blood pressure.

In controlled clinical studies, an immediate-release dosage form of metoprolol was an effective antihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics at dosages of 100-450 mg daily. TOPROL-XL, in dosages of 100 to 400 mg once daily, produces similar β1-blockade as conventional metoprolol tablets administered two to four times daily. In addition, TOPROL-XL administered at a dose of 50 mg once daily lowered blood pressure 24-hours post-dosing in placebo-controlled studies. In controlled, comparative, clinical studies, immediate-release metoprolol appeared comparable as an antihypertensive agent to propranolol, methyldopa, and thiazide-type diuretics, and affected both supine and standing blood pressure. Because of variable plasma levels attained with a given dose and lack of a consistent relationship of antihypertensive activity to drug plasma concentration, selection of proper dosage requires individual titration.
Participants will receive the entire multicomponent safer driving behavioral intervention from arm 2. This arm will be identical to Arm 3, except there will be a shared pot financial incentive instead of a raffle. Participants that abstain from phone use while driving and seat belt adherence earn an equal share of prize money allocated for the entire group.
After subcutaneous injection of 1 mL of 2% lidocaine, a nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach from lateral to medial direction. After the needle is penetrated the nerve sheath, the nerve stimulator is then turned on, and the stimulation current starts at 0.5mA. If hand muscle twitching is observed even at 0.3 mA, local anesthetics 30 mL (lidocaine mixed with epinephrine) is injected.
Following a three-week run-in period (Period I) during which participants received placebo, participants entered into a 12-week double-blind treatment period (Period II) during which they received daily doses of either one of three doses of MK-0873 or placebo. Period I and Period II made up the Base Study. Following the 12-week treatment period in the Base Study, participants were invited to continue in an optional 12-week double-blind extension study (Period III, EXT1). Participants who received any dose of MK-0873 in the Base Study continued on MK-0873 2.5 mg daily in Period III while participants in the placebo arm of the Base Study continued on placebo daily. Following EXT1, participants were invited to continue in an optional open-label second extension study (EXT2) which was to last 80 weeks (Period IV: 28 weeks, Period V: 52 weeks). In EXT2, participants who had been taking MK-0873 2.5 mg in the Base Study were allocated to MK-0873 2.5 mg plus usual care, while participants who had been taking the other two doses of MK-0873 or placebo in the Base Study were allocated to either MK-0873 2.5 mg plus usual care or to usual care alone.
In recent years, the analysis of big data database combined with computer deep learning has gradually played an important role in biomedical technology. For a large number of medical record data analysis, image analysis, single nucleotide polymorphism difference analysis, etc., all relevant research on the development and application of artificial intelligence can be observed extensively. For clinical indication, patients may receive a variety of cardiovascular routine examination and treatments, such as: cardiac ultrasound, multi-path ECG, cardiovascular and peripheral angiography, intravascular ultrasound and optical coherence tomography, electrical physiology, etc... The current study is for the investigative cardiovascular team to take the advantage that in addition to the examination and treatment the participants should appropriately receive, the investigators can also analyze the individual differences and using the "deep learning methodology" to analyze the difference in physical fitness, therapeutic effectiveness and the consideration in the safety of the treatment. The additional goal of this study is to improve the quality of health care, the realization of cardiovascular "precise medicine" especially with personal difference on genetic variation.

This study will analyze the differences in the individualization of cardiovascular disease between diseases and other subjects to further improve the quality of care for clinical patients. By using artificial intelligence deep learning system, the investigators hope to not only improve the diagnostic rate and also gain more accurately predict the patient's recovery, improve medical quality in the near future.
The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
Chronic migraine affects about 2 percent of all adults. Currently there are no effective preventative treatments to deal with this disabling condition. Three randomized, placebo-controlled trials found that topiramate was an effective, safe and generally well-tolerated drug for treating chronic migraine. As a result of these trials, topiramate is becoming the standard treatment among headache specialists. Experts agree that treatment with combinations of preventive agents is required in the majority of individuals with chronic migraine for maximal headache relief. No randomized trials have assessed the value of frequently used combinations of preventive agents for chronic migraine.

The goal of this trial is to determine if adding a second drug to topiramate treatment will further reduce the headache burden for people with this condition. In the study, 250 participants with chronic migraine will be randomized to two groups - treatment with topiramate and propranolol or topiramate and placebo. Participants will be followed for six months.
Background: Recurrent, excessive, uncontrollable worry about multiple topics is common in older adults, but it is not well studied. This significant worry can negatively affect thinking, and it is associated with poorer sleep, more depression, and worse general health. Despite its prevalence, researchers have not studied significant worry enough, particularly in low-income racial and ethnic minority populations. We know these groups are unlikely to have adequate mental health care. We also know that older adults and minorities prefer treatments for worry that do not require medication, and that these kinds of treatments can be effective. Additional tests of treatments that do not involve drugs are needed in low-income racial and ethnic minority populations. Such person-centered research could expand access to appropriate care.

Objectives: The study team plans to compare two approaches, one called Calmer Life (CL) and another called Enhanced Community Care (ECC). CL helps individuals by providing worry-reduction skills and resource counseling for basic needs in a flexible, culturally supportive manner. ECC relies on standard information and resource counseling. The study will answer three questions. First, compared to ECC, is CL more effective at relieving significant worry? Second, which one is more effective at reducing anxiety and depression and improving sleep, ability to do daily activities, and use of medical services? Third, are improvements still present three months after treatment concludes?

Methods: In agreement with our community partners and governed by a council of community leaders, consumers, and providers from low-income minority communities, we will conduct the study. This community-academic partnership, created four years ago, introduced CL to the community. Case managers and community health workers from partner organizations were trained to implement CL. They taught worry-reduction skills and helped participants increase their use of community resources. Content was flexible so that participants could choose which skills to learn and whether or not to include religion or spirituality. They also could learn skills at home, by telephone, or in the community. In a new, larger comparison study, we will enroll 120 women and 30 men who are 50 years of age or older with significant worry. Most (80 percent) will be African American, and 70 percent will have income below poverty. Participants will be assigned by chance to CL or ECC and treated for six months. Brief assessments at enrollment and at six and nine months will rely on participants' reports. Differences will be measured statistically.
Adult rowers, aged between 18 and 25, training \>6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
The present invention provides methods and compositions for stimulating an immune response or modulating cell signal transduction in a host by administering to said host a composition comprising at least three biomodulatory molecules connected by at least one cross-linking agent forming a chain or matrix wherein the chain or matrix functions as an immuno-stimulatory adjuvant to activate an immune accessory cell. The composition may comprise one or more types of biomodulatory molecules selected from the group consisting of cytokines, bacterial molecules, receptor ligands, antigen binding fragments of antibodies, heat shock proteins, and integrins. The composition may further comprise one or more disease-specific antigens to stimulate an immune response. The disease-specific antigens may be selected from the group consisting of tumor-associated antigens, infectious disease-associated antigens, autoimmune-associated antigens, parasitic antigens, bacterial antigens, and viral antigens. In addition the composition may further comprise a solid support to which the cross-linked biomodulatory molecules are affixed. The solid support may be selected from the group consisting of Dextran, chitosan, alginate, poly-DL lactide polyglycolide, polyglycolide, or alum.
This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
Alkali metal and ammonium zirconyl carbonates (AZC) may be used as active antiperspirant ingredients when converted to complexes with various acidic antiperspirant agents, including particularly the highly acidic zirconium compounds. The acidic antiperspirant agent activates the zirconium in the zirconyl carbonate to an acidic, active antiperspirant species. The zirconyl carbonate comprises about 2 to 35 weight percent of the complex, and the antiperspirant activating agent is present in such an amount that the pH of a 5 to 20 weight percent aqueous solution of the complex will be about 3 to 6. Potassium and ammonium zirconyl carbonates are preferred, but sodium may also be used if the complex is kept in solution. The acidic, antiperspirant activating agent is preferably a zirconium oxy salt or zirconium hydroxy salt, such as a zirconium hydroxy halide. However, other water soluble, polyvalent metal salts of strong acids may be used, particularly aluminum halides and basic aluminum compounds. In addition, the complex may include organic complexing agents such as urea, amino acids and hydroxy carboxylic acids. The complexes may be used in various conventional antiperspirant forms, including aqueous solutions, aerosol sprays, powder-in-oil aerosol sprays, creams, lotions, cream sticks, etc.
Gastrointestinal dysfunction(GID) is frequently seen in critically ill patients and is associated with worse clinical outcomes. Medical nutrition therapy (MNT) is an integral part of critical care, which may be associated with improved clinical outcomes. The international practical guidelines or consensus for critically ill patients were recommended based on the results of previous investigations. However, the rationale of these recommendations was controversial by the findings of the most recent studies. This review discusses the current developments and controversy about nutritional assessment of critically ill patients prior to medical nutrition therapy, early enteral nutrition, target of trophic feeding, and time to target achievement. This review summarizes the available evidence of MNT in critically ill patients and offers suggestions for clinical practice and future research.
BACKGROUND: Neonates with intrauterine growth retardation (IUGR) may present with fatal complications and permanent serious consequences. Vitamin status may influence fetal development. In this study we assessed vitamin A, E and D concentrations in umbilical cord blood in newborns with IUGR.
METHODS: Maternal data were obtained. Neonatal assessment included; age of gestation calculated from last menstrual period, Ultrasound (U/S), new Ballard, Apgar scores and anthropometric measurements including; Head circumference, length and weight. WHO growth percentile curves were used. Vitamin A, E and D in cord blood samples were measured by high performance liquid chromatography (HPLC) and ELISA consecutively.
RESULTS: A total of 86 full term newborns were enrolled in this study, 42 (48.8%) with IUGR with gestational age (33.59 ± 1.20) week by U/S and 44 (51.2%) appropriate for gestational age neonates with gestational age (38.70 ± 1.50). Ballard and Apgar scores (p < 0.05) and Z scores for weight, length and head circumference (p < 0.001) at birth were significantly lower in neonates with Intrauterine growth retardation (IUGR) than appropriate for gestational age (AGA) neonates. The levels of Vitamin A, E and D were significantly lower in the IUGR group than the AGA (p < 0.05) for all. Significant positive correlations of weight with vitamin A, and E cord blood levels were found (p < 0.05), while length was significantly positively correlated only with vitamin A (p < 0.05). Head circumference showed significant positive correlations with the three vitamins (p < 0.05) for all.
CONCLUSION: Neonates with IUGR had significantly lower levels of Vitamin A, E and D than AGA neonates. Significant positive correlations of weight with vitamin A, and E cord blood levels was detected, while neonatal length was associated only with vitamin A level. The present study highlights the significance of nutritional policies for inhibiting deficiency of these vitamins during pregnancy and childhood.